• VOD-new-1
  • linkedin

Compounding Research Studies

Results of this study showed that Clarifying Base has the ability to inhibit the growth of P. acnes at a concentration of 15% when used alone, and 10% when in conjunction with benzoyl peroxide.

Basal cell carcinoma is a type of skin cancer that often leads to surgical excision of the affected area, which results in destruction of the tissues and skin scarring.

One base suspends it all. SuspendIt's superior anti-sedimentation technology can deliver everything you need to compound oral suspensions - it's the all-in-one oral suspension base.

The ability of MucoLox to prolong contact between the medication and the site of action (vaginal mucosa) has the potential to increase the efficacy of the compounded medication and to reduce the need for frequent dosing.

The ability of MucoLox to prolong contact between the medication and the site of action (nasal mucosa) has the potential to increase the efficacy of the compounded medication and to reduce the need for frequent dosing.

The ability of MucoLox to prolong contact between the medication and the site of action (oral mucosa) has the potential to increase the efficacy of the compounded medication and to reduce the need for frequent dosing.

The ability of MucoLox to prolong contact between the medication and the site of action has the potential to increase the efficacy of the compounded medication and to reduce the need for frequent dosing.

Results have demonstrated that PracaSil-Plus did not contribute to the progression of melanoma cells when compared to untreated tissues.

The objective of this study is to compare the toxicity profile of LoxaSperse against a known toxic (Polysorbate 20 NF) and commercial nontoxic (Monohydrate Lactose inhalation grade) agent in the pulmonary system using an in vitro model of the human respiratory tract tissue.

A 75-year-old Caucasian woman presented with burns on the front and back of her right shoulder after multiple (30) sessions of radiation therapy. An open wound developed on the burned area, causing her severe pain and discomfort. She applied PracaSil™-Plus, a proprietary anhydrous silicone scar base, twice daily on her shoulder and the open wound healed completely within 11 days.

The oral dosing of progesterone has limitations due to poor absorption (low bioavailability) and short half-life of the drug. Progesterone must be bioavailable in order to be effective for hormonal replacement therapy (HRT).

A 51-year-old male received a third-degree burn on his back, neck and ear after being involved in an explosion. PracaSil™-Plus, a proprietary anhydrous silicone scar base, was applied three times per week to the affected area, which resulted in complete healing within 21 days.

LoxaSperse™ is a powder excipient base used for nasal nebulization and irrigation designed to improve dispersibility and solubility of Active Pharmaceutical Ingredients (APIs).

The efficacy of PracaSil-Plus in the improvement of scar appearance was evaluated by visual and instrumental methods in an eight-week, randomized, double-blind, controlled study.

A compounded medicine using PracaSil-Plus (PCCA Formula #10843) was applied topically in an open wound located on the leg of a diabetic patient, with outstanding healing results.

A compounded medicine using PracaSil-Plus (PCCA Formula # 10843), was applied topically to the right and left elbow injuries caused by a fitness competition, which resulted in considerable healing progress.

A 72-year-old caucasian male reported extreme pain, scaling, redness, and irritation on his burns resulting from multiple radiation treatments. He applied PracaSil™-Plus, a proprietary anhydrous silicone scar base, several times per day as needed to the lateral side of the face and neck which resulted in complete healing within 14 days.

The intent of this study was to evaluate results of purposeful inoculation of the formulations with microorganisms specified in USP <51> (The United States Pharmacopeial Convention, 2013a), for nasal and inhalation use with modified Antimicrobial Effectiveness Test (AET) methodology and to quantitatively determine the in vitro effectiveness of formulations containing LoxaSperse to prevent microbial proliferation and/or kill the organisms.

The intent of this study was to evaluate results of purposeful inoculation of the formulations with microorganisms specified in USP <51> (The United States Pharmacopeial Convention, 2013a), for nasal and inhalation use with modified Antimicrobial Effectiveness Test (AET) methodology and to quantitatively determine the in vitro effectiveness of formulations containing LoxaSperse to prevent microbial proliferation and/or kill the organisms.

The in vitro antimicrobial activity of itraconazole in a LoxaSperse formulation was evaluated against Candida albicans biofilms and compared to the same activity of reference antifungal drugs (itraconazole, fluconazole and amphotericin B), in order to verify the benefits of the LoxaSperse formulation.

PCCA tested the performance of PCCA Formula #10337 (gentamicin 80 mg/LoxaSperse), and measured its efficacy against microbial activity when mixed with sterile water.

PCCA tested the performance of PCCA Formula #10341 (budesonide 0.5 mg in a LoxaSperse mixture) and measured its efficacy against microbial activity when mixed with sterile water.

The physical and microbiological properties of LoxaSperse were characterized by three laboratory tests performed with LoxaSperse and LoxaSperse with itraconazole.

The purpose of this study was to evaluate the potential of LoxOral to enhance the dissolution properties of piroxicam and to evaluate its utility in comparison to MCC delivery systems.

The purpose of this study was to evaluate the potential of LoxOral to enhance the dissolution properties of ketoconazole and to evaluate its utility in comparison to MCC delivery systems.

This Abstract Poster Presentation presented at PAINWeek 2013 (4 - 7 Sep 2013) in Las Vegas, Nevada deals with evaluation of the in vitro human trunk skin percutaneous absorption of Ketamine HCl, Gabapentin, Clonidine HCl and Baclofen using the Franz Skin Finite Dose Model

This Abstract Poster Presentation presented at the FIP World Congress Dublin, Ireland (31 Aug – 5 Sep 2013) deals with the complexites and opportunities presented through compounding for pediatric patients.

Summary: PracaSil-Plus, a proprietary anhydrous silicone base, was applied topically on an infant’s facial scalding burn and on a toddler’s diaper rash, resulting in considerable progress in both pediatric case studies.

The efficacy of PracaSil-Plus in scar therapy treatment was evaluated by visual and instrumental methods in an eight-week, randomized, double-blind, controlled study.

PracaSil-Plus, a proprietary anhydrous silicone base, was applied topically on ankle scars (old & new) and an overall improvement of both ankle scars was observed in a very short period of time.

PracaSil-Plus, a proprietary anhydrous silicone base, was applied topically on ankle scars (old & new) and an overall improvement of both ankle scars was observed in a very short period of time.

A compounded medicine containing PracaSil-Plus (PCCA Formula #10649) was applied topically on facial scars (old) and an overall improvement of the facial complexion was observed following only 3 weeks.

Lipoderm and Lipoderm ActiveMax Now Proven to Deliver Lorazepam Into and Through Human Skin

Lipoderm® Proven to Deliver Ketamine HCl, Gabapentin, Clonidine HCl and Baclofen Simultaneously Through Human Skin In Vitro – FIRST STUDY OF ITS KIND

Lipoderm with Tramadol Performs Well in Feline Inner Ear Test

PCCA Lipoderm now PROVEN to Deliver the NSAID Ketoprofen Through Human Skin In Vitro

PCCA Lipoderm now PROVEN to Deliver the NSAID Ketoprofen Through Human Skin In Vitro